Denosumab — CPB 0804 | AETNA Coverage Update

Aetna modified CPB 0804 covering denosumab (Prolia, Xgeva, and eight biosimilars each), effective December 20, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its denosumab coverage policy under CPB 0804 to reflect a dramatically expanded biosimilar landscape — eight Prolia biosimilars and eight Xgeva biosimilars now fall under this policy. The primary billing codes affected include J0897 (denosumab injection), Q5136, Q5157, Q5158, and Q5159 for biosimilar products, plus CPT 96372 for subcutaneous injection administration. If your practice bills denosumab for osteoporosis or oncology indications, this update touches your charge capture, your prior authorization workflows, and your medical necessity documentation — all at once.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna (CPB 0804)
Policy	Denosumab — CPB 0804 | Aetna Coverage Update
Policy Code	CPB 0804
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Endocrinology, Oncology, Rheumatology, Internal Medicine, Orthopedics
Key Action	Update charge capture for biosimilar HCPCS codes Q5136, Q5157, Q5158, Q5159 and verify precertification is in place before billing any denosumab product

---

Aetna Denosumab Coverage Criteria and Medical Necessity Requirements 2025

The real issue with this update isn't the drug — it's the sheer number of biosimilar products now covered under a single policy, each with its own HCPCS code. Your billing team needs to map each product to the right code before the first claim goes out.

Aetna's denosumab coverage policy splits into two tracks: Prolia (and its biosimilars) for osteoporosis indications, and Xgeva (and its biosimilars) for oncology indications. Medical necessity criteria are distinct for each track. Getting the tracks mixed up is a fast path to claim denial.

Prolia and Biosimilars — Osteoporosis Indications

Aetna considers Prolia or its biosimilars medically necessary for postmenopausal osteoporosis when the member has a history of fragility fractures — defined as a low-trauma fracture from a force similar to a fall from standing position. That's the cleanest path to approval.

If there's no fracture history, coverage still applies when the member has a pre-treatment T-score ≤ -2.5. It also applies when the member has osteopenia (T-score between -1 and -2.5) with a high FRAX probability — but that osteopenia-plus-FRAX path requires at least one additional criterion. Those secondary criteria include indicators of very high fracture risk (advanced age, frailty, glucocorticoid use, T-score ≤ -3, or increased fall risk), inadequate response or intolerance to prior injectable osteoporosis therapy like zoledronic acid (J3489), teriparatide (J3110), or abaloparatide, or inadequate response or intolerance to oral bisphosphonate therapy. A T-score already at ≤ -2.5 stands on its own — the secondary criteria stack applies to the osteopenia-with-high-FRAX path specifically.

For osteoporosis in men, the bar is slightly different. Coverage applies when the member has a prior osteoporotic vertebral or hip fracture, a T-score ≤ -2.5 or osteopenia with high FRAX probability, or an inadequate response or intolerance to prior bisphosphonate therapy. No secondary criteria stack required — any one of those three gets you there.

Glucocorticoid-induced osteoporosis requires both conditions to be met. The member must be on or starting glucocorticoid therapy at a prednisone-equivalent dose of ≥ 2.5 mg/day for three months or more. Then they must either have an inadequate response or intolerance to bisphosphonate therapy, or meet at least one of the high-risk criteria including prior fragility fracture.

Prior Authorization Is Mandatory — No Exceptions

Precertification of all denosumab products is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277. This isn't a soft requirement — billing without precertification in place will result in claim denial.

Aetna uses specific prior authorization pathways for Prolia-track vs. Xgeva-track indications. Make sure your PA requests reference the correct indication category and the correct HCPCS code for the specific product being dispensed.

Xgeva and Biosimilars — Oncology Indications

The Xgeva track covers prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of giant cell tumor of bone. The oncology indications involve different ICD-10-CM codes — pulling from the C-code range — and different clinical documentation requirements. Your medical necessity documentation needs to reflect the specific oncology indication and line it up against the correct coverage criteria in CPB 0804.

The policy includes both CPT 96372 and the chemotherapy administration codes in the 96401–96450 range. The source data does not assign these codes to specific indication tracks. Review the full CPB 0804 to confirm which administration codes apply to your specific claim before billing.

---

Aetna Denosumab Exclusions and Non-Covered Indications

The policy explicitly does not cover combined denosumab and chemotherapy for non-small cell lung cancer (NSCLC). The ICD-10 codes C33–C34.92 appear in the policy specifically flagged as not covered for this combination. If you have patients on a denosumab-plus-chemo protocol for NSCLC, don't expect reimbursement under this policy — it won't come.

This is a meaningful exclusion for oncology practices treating lung cancer patients with bone metastases. The temptation is to bill Xgeva for bone mets while the patient is also on chemotherapy for NSCLC. Aetna has drawn a hard line here.

Any denosumab use outside the listed indications — postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, cancer treatment–induced bone loss, Xgeva oncology indications, giant cell tumor of bone — will be considered not medically necessary. Document the specific covered indication clearly on every claim.

---

Coverage Indications at a Glance

†Note on biosimilar HCPCS codes: Q5136, Q5157, Q5158, and Q5159 correspond to four specific biosimilar products (denosumab-bbdz, denosumab-bmwo, denosumab-bnht, and denosumab-dssb respectively). Four additional biosimilar products — denosumab-desu, denosumab-kyqq, denosumab-nxxp, and denosumab-qbde — do not have assigned HCPCS Q-codes in the current policy data. If your practice administers any of these products, consult the full CPB 0804 and your billing consultant before submitting claims.

---

Aetna Denosumab Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Denosumab Under CPB 0804

Key HCPCS Codes — Denosumab Products

Note: Four additional biosimilar products — denosumab-desu, denosumab-kyqq, denosumab-nxxp, and denosumab-qbde — do not have assigned HCPCS Q-codes in the current policy data. Consult the full CPB 0804 and your billing consultant before billing these products.

Administration CPT Codes

Code	Type	Description Copy
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
96401–96450	CPT	Chemotherapy administration codes (range) — listed in CPB 0804; confirm applicability to your specific claim against the full policy

Note: The source policy assigns both 96372 and the 96401–96450 range to the same group ("Other CPT codes related to the CPB") without indication-specific distinctions. Do not assume these codes map exclusively to a single track. Verify with the full CPB 0804 before billing.

Key ICD-10-CM Diagnosis Codes

The full policy lists 133 ICD-10-CM codes. The C34.x range represents the key exclusions for NSCLC combination therapy. Review the full CPB 0804 code list at the Aetna source before finalizing your ICD-10 mappings for oncology claims.

---